At 7: am on January 1, 222, the mother of a 4-year-old child with spinal muscular atrophy (SMA) in Zaozhuang City, Shandong Province was overjoyed after receiving targeted treatment. Nocicanakan sodium injection is the first imported drug approved for the treatment of spinal muscular atrophy in China. It can modify the protein produced by genes and provide treatment for patients, so it is called spinal muscular atrophy? Life-saving drugs? . When entering the China market in 219, the price of each needle was nearly 7, yuan, which was difficult for many patients' families to afford. On December 3, 221, medical insurance bureau announced that 74 new drugs were included in the national medical insurance system, among which Nosinken injection was listed as? Expensive life-saving drugs? . After eight rounds of negotiations, the drugs entered the new version of the medical insurance drug list. Bottom price? It is 33, yuan per needle. A long time ago, 1.2 million injections of cancer drugs were not covered by health insurance, which made many lymphoma patients feel uneasy.
In February, 219, National Medical Products Administration officially approved 7, bottles of Noxinneng Sodium Injection, and about 6 bottles, or about 4.2 million RMB, were needed each year. After that, it will be injected every four months for life. This is a very serious disease, but it can be cured and expensive. Thousands of families are finally waiting for the drugs to go on the market, but few people can afford them. In China, the total number of polio patients with a population of 1.4 billion is 2, to 3,. In China, the proportion of SMA patients is very small, which is a rare disease. If you look at the cost of drugs, the cost of drugs is really not very expensive, otherwise it will not drop from nearly 71, injections to 3, injections.
in any case, the price of drugs depends not only on the production cost, but also on the early development cost. To prepare a drug to treat this disease, pharmaceutical companies need to invest a lot of manpower, material resources and financial resources, and it will take more than 1 years for this drug to go on the market. The average total cost of each drug is about $1 billion, and the actual cost of research and development may be higher for rare diseases like SMA. The purpose of pharmaceutical companies is to make profits, which is in line with economic principles. Without profit, there is no incentive to invest in research and development, which is why the initial pricing is very expensive. However, high prices mean that sales may not increase, and the price of 7, stitches is unbearable for ordinary families in China.
more importantly, this drug needs to be patented before it goes on the market. Once the patent protection period expires, many pharmaceutical companies will copy it. The term of patent protection is generally 2 years. In a short period of time, enterprises need to quickly recover the R&D cost and realize a certain profit, thus promoting the continuous research and development of drugs for other diseases. In addition to Bojian's drugs, Novartis's Sofarevir is priced at $2.1 million in the United States and 167.7 million yen in Japan. It can be seen that the negotiated price of medical insurance in China is undoubtedly the lowest in the world. Compared with other developed countries, China's market is bigger, and the soul negotiation of medical insurance bureau has contributed to this result.